Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting

• DOI: 10.1186/s12967-018-1511-x
• Publication Date: 2018-05-16T12:36:27Z
• Authors: Chiara Mandoj; Laura Pizzuti; Domenico Sergi; Isabella Sperduti; Marco Mazzotta; Luigi Di Lauro; Antonella Amodio; Silvia Carpano; Anna Di Benedetto; Claudio Botti; Francesca Ferranti; Anna Antenucci; Maria Gabriella D...; Paolo Marchetti; Silverio Tomao; Giuseppe Sanguineti; Antonio Giordano; Marcello Maugeri-...; Gennaro Ciliberto; Laura Conti; Patrizia Vici; Maddalena Barba
• Keywords: Genetics and Molecular Biology (all); Survival; Coagulation activation; Early breast cancer; Prognostic score; Survival; Biochemistry, Genetics and Molecular Biology (all); 610; Breast Neoplasms; Biochemistry; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; 616; Biomarkers, Tumor; Humans; Blood Coagulation; Coagulation activation; Research; Early breast cancer; R; early breast cancer; coagulation activation; prognostic score; survival; Middle Aged; Prognosis; Survival Analysis; 3. Good health; Prognostic score; Multivariate Analysis; Medicine; Female

Cancer and coagulation activation are tightly related. The extent to which factors related both these pathologic conditions concur patient prognosis intensely animates the inherent research areas. study herein presented aimed development of a tool for assessment stratification risk death disease recurrence in early breast cancer. Between 2008 2010, two hundreds thirty-five (N: 235) patients diagnosed with stage I–IIA cancer were included. Data on demographics clinic-pathologic features collected course face-to-face interviews or actively retrieved from clinical charts. Plasma levels plasminogen activator inhibitor type 1 (PAI-1), fragment + 2 (F1 2), thrombin antithrombin complex (TAT), factor VIII (FVIII), D-dimer (DD) measured at diagnosis prior any therapeutic procedure, including surgery. was computed terms overall survival (OS), primary outcome. For subset (N = 62), free (DFS) also assessed as measure recurrence. Median follow up 95 months (range 6–112 months). Mean age 60.3 ± 13.4 years. cases more commonly intraductal carcinomas 204; 86.8%), pT1 (131; 55.7%), pN0 (141; 60%) G2 (126; 53.6%). Elevated PAI-1 (113; 48.1%) represented most frequent abnormality, followed by higher F1 (97; 41.3%), DD (63; 27.0%), TAT (34; 40%), FVIII (29; 12.3%). In univariate models OS, age, pT, DD, prognostically relevant. multivariate (p 0.043), pT 0.001), 0.029) 0.087) confirmed. smaller subgroup 62 patients, lymph node involvement, percent expression estrogen receptors impacted DFS significantly. We developed OS patient- cancer-related along biomarkers cohort BC patients. Further studies warranted validate our prognostic model setting eventually extend its application evaluation advanced other cancers.